Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wizz Air reports 10.8pc rise in April passengers

(Sharecast News) - Wizz Air carried 5.4 million passengers in April, a year-on-year increase of 10.8%, as the favourable timing of Easter supported a strong start to its financial year. The FTSE 250 low-cost airline said in an update on Friday that its capacity rose 11.4% compared with the same month last year, while the load factor slipped 0.5 percentage points to 89.8%.

It said the seasonal spike in demand from Easter falling entirely within April was expected and consistent with historical trends, although the holiday period also drove one-directional visiting friends and relatives (VFR) traffic that modestly weighed on load factor.

Over the rolling 12-month period, Wizz Air carried 63.9 million passengers, up 3.1% year-on-year, with capacity up 1.9% and load factor improving by one percentage point to 91.1%.

Wizz also advanced its environmental initiatives during the month, launching its 'Flying Towards Net Zero' carbon roadmap.

The strategy placed sustainable aviation fuel at the centre of its decarbonisation plans, with the potential to achieve an additional 25% cut in emissions by 2030.

Carbon dioxide emissions per revenue passenger kilometre fell by 2.5% year-on-year in April, reaching 51.3 grams, maintaining the airline's position as one of Europe's lowest-emission carriers.

At 0952 BST, shares in Wizz Air were down 0.41% at 1,711p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.